RC
MRNA icon

Reik & Co’s Moderna MRNA Stock Holding History

Reik & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,898
Closed -$327K – 57
2024
Q3 		$327K Buy
4,898
+120
+3% +$11K 0.08% 47
2024
Q2 		$567K Sell
4,778
-2
-0% -$253 0.15% 37
2024
Q1 		$509K Hold
4,780
– – 0.13% 40
2023
Q4 		$475K Hold
4,780
– – 0.13% 39
2023
Q3 		$494K Buy
4,780
+500
+12% +$55.8K 0.14% 38
2023
Q2 		$520K Hold
4,280
– – 0.14% 40
2023
Q1 		$657K Sell
4,280
-105
-2% -$17.3K 0.19% 38
2022
Q4 		$788K Sell
4,385
-650
-13% -$106K 0.23% 33
2022
Q3 		$595K Buy
5,035
+400
+9% +$60.7K 0.19% 37
2022
Q2 		$662K Hold
4,635
– – 0.19% 36
2022
Q1 		$798K Buy
4,635
+1,400
+43% +$236K 0.2% 37
2021
Q4 		$822K Buy
3,235
+885
+38% +$259K 0.2% 35
2021
Q3 		$904K Buy
2,350
+350
+18% +$129K 0.23% 33
2021
Q2 		$470K Hold
2,000
– – 0.12% 44
2021
Q1 		$262K Buy
+2,000
New +$290K 0.07% 48

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Reik & Co's MRNA Position: Q4 2024 in Review

Reik & Co sold out of Moderna (MRNA) in Q4 2024, closing a stake of 4,898 shares — an estimated $327K sold.

Reik & Co first reported a position in MRNA in Q1 2021 and held it in 15 quarters. The position peaked at $904K in Q3 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Reik & Co reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Reik & Co sold 4,898 Moderna shares in Q4 2024, an estimated $327K.
  • Reik & Co first reported a position in Moderna in Q1 2021 and held it in 15 quarters.
  • Reik & Co's Moderna position peaked at $904K in Q3 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Reik & Co's 13F filing for Q4 2024, filed 29 Jan 2025.